Godt eksempel på en aksje man skulle solgt da momentet var der. Nå er det helt stille og kursen har halvert seg. Nå er det bare å håpe det skjer noe snart igjen, for sent å trade tenker jeg.
Har du fått med deg dette, det historiske sektorkrakket? Du skulle solgt alle FoU aksjer i fjor høst.
Alltid lurt å selge på topp. Aldri mulig å spå fremtiden. Så slike kommentarer blir 
Selskapet rekrutterer fortsatt best i klassen, er finansiert over avlesninger og inn i 2024. Så her slipper du i alle fall å bli vannet ut. I H2 får man mer data og TET-plattformen vil komme i spill.
Å kunne kjøpe aksjer til samme kurs som høsten 2020, etter alt som har materialisert seg siden den gang, kan vise seg å bli svært attraktivt.
5 Likes
Du har et ganske solid poeng der ja…
1 Like
Ultimovacs’ Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy
26 Likes
Oslo, 25 May 202 2 : Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced the publication of long-term follow-up data on UV1 in the Journal for ImmunoTherapy of Cancer ( JITC ). The data show that dynamic UV1 specific immune responses last up to 7.5 years, are associated with longer survival and are enhanced when UV1 is used in combinations with checkpoint inhibitors.
“It is important to be able to share this validating data with our research and clinical colleagues through JITC . The data demonstrate highly durable UV1-induced immune responses that are associated with substantially longer overall survival and boosted by checkpoint inhibitors. This is strong support for Ultimovacs’ broad Phase II program combining UV1 with checkpoint inhibitors across five different cancer indications,” said Carlos de Sousa, Chief Executive Officer of Ultimovacs.
The Journal for ImmunoTherapy of Cancer is the peer-reviewed open access journal of the Society for Immunotherapy of Cancer. Ultimovacs’ paper in JITC reports data from three Phase I/IIa clinical trials on Ultimovacs’ cancer vaccine lead UV1 in three separate cancer indications – malignant melanoma, non-small cell lung cancer (NSCLC) and prostate cancer.
The data demonstrate that UV1 vaccination leads to dynamic immune responses in patients, notably the induction of memory T cells with a cytokine profile involving the production of IFN-gamma and TNF-alpha. Furthermore, the paper demonstrates the development of a UV1-specific immune response associated with longer survival time across the three cancer types.
Adding checkpoint inhibitors boosts the potentially protective UV1 response. UV1-specific immune responses occurred earlier and more frequently in patients with malignant melanoma, where UV1 was combined with the checkpoint inhibitor ipilimumab, than in patients with NSCLC or prostate cancer where no checkpoint inhibitor was involved. Around 91% of patients with malignant melanoma showed a detectable immune response within three months.
The JITC paper is available at the JITC website: “Ellingsen EB, Aamdal E, Guren T, et al. Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials . Journal for ImmunoTherapy of Cancer 2022;0:e004345. doi:10.1136/jitc-2021-004345.
The data was also presented as a poster at the Cancer Immunotherapy (CIMT) annual meeting in Mainz, Germany, 10-12 May 2022. The JITC paper and the CIMT poster can be found on the Company website.
8 Likes
Er dette nyheter eller kjent fra før?
1 Like
The data was also presented as a poster at the Cancer Immunotherapy (CIMT) annual meeting in Mainz, Germany, 10-12 May 2022. The JITC paper and the CIMT poster can be found on the Company website.
Artikkelen rommer naturlig nok vesentlig mer informasjon.
2 Likes
Nok til at det er kursdrivende tror du?
Ingen aning. Ikke mye som er kursdrivende for tiden. Det er så tynn likviditet at ørlite volum inn eller ut beveger kursen kraftig.
Håpet er jo at sektoren våkner til liv igjen snart. Og da er det mange som vil se på Ultimovacs først. Når det først skjer, så vil det gå raskt.
Selv om sektoren skulle skjendes videre, så vil kjøpspresset øke åkke som etter hvert som man får mer pembro-data, konkretisering av planer/ambisjoner for TET-plattformen og avlesningene nærmer seg.
Spørsmålet er når inngangen blir best mulig. Ikke sikkert den blir bedre enn nivået aksjen befinner seg i dag.
Abstract
Background Therapeutic cancer vaccines represent a promising approach to improve clinical outcomes with immune checkpoint inhibition. UV1 is a second generation telomerase-targeting therapeutic cancer vaccine being investigated across multiple indications. Although telomerase is a near-universal tumor target, different treatment combinations applied across indications may affect the induced immune response. Three phase I/IIa clinical trials covering malignant melanoma, non-small cell lung cancer, and prostate cancer have been completed, with patients in follow-up for up to 8 years.
Methods 52 patients were enrolled across the three trials. UV1 was given as monotherapy in the lung cancer trial and concurrent with combined androgen blockade in the prostate cancer trial. In the melanoma study, patients initiated ipilimumab treatment 1 week after the first vaccine dose. Patients were followed for UV1-specific immune responses at frequent intervals during vaccination, and every 6 months for up to 8 years in a follow-up period. Phenotypic and functional characterizations were performed on patient-derived vaccine-specific T cell responses.
Results In total, 78.4% of treated patients mounted a measurable vaccine-induced T cell response in blood. The immune responses in the malignant melanoma trial, where UV1 was combined with ipilimumab, occurred more rapidly and frequently than in the lung and prostate cancer trials. In several patients, immune responses peaked years after their last vaccination. An in-depth characterization of the immune responses revealed polyfunctional CD4+ T cells producing interferon-γ and tumor necrosis factor-α on interaction with their antigen.
Conclusion Long-term immunomonitoring of patients showed highly dynamic and persistent telomerase peptide-specific immune responses lasting up to 7.5 years after the initial vaccination, suggesting a plausible functional role of these T cells in long-term survivors. The superior immune response kinetics observed in the melanoma study substantiate the rationale for future combinatorial treatment strategies with UV1 vaccination and checkpoint inhibition for rapid and frequent induction of anti-telomerase immune responses in patients with cancer.
4 Likes
Takker
Jeg sitter helt stille i båten og venter på bedre tider 
1 Like
Etter ‘Abstract’ og ‘Background’ er dette er tunge greier. Så vidt jeg forstår er en slags oppsummering av denne artikkelen at UV1 skaper en immunrespons i de fleste pasientene, at de fleste av disse pasientene har forlenget og fornyet immunrespons (etter mange år) på de samme antigenene, og at kombinasjonen med en sjekkpunkthemmer bidrar til begge deler (dette siste tror jeg er nytt: at altså tillegg av CPI bidrar til økt IR sent i forhold til kun UV1). Men alle viktigst; at immunrespons på peptidene i UV1 både tidlig og sent er korrelert med lang overlevelse.
Det aller mest imponerende Ultimovacs har av data foreløpig er antallet complete responders (målbart kreftfrie) i føflekkreftstudien med 30 pasienter, som altså startet etter disse tre artikkelen handler om. Det kan skyldes tilfeldigheter at UV1 hjelper en del pasienter med å bli friskere i denne studien (PR), men at så mange blir målbart kreftfrie (CR) er ekstremt lite sannsynlig at er tilfeldig. Og at UV1 hjelper pasientene lenge etter endt behandling og faktisk klarer å utradere alle tumorer kan være forklart av følgende i slutten av artikkelen:
“The longevity of the induced IR and the persisting proliferative capacity of the T cells provide reasons for optimism for UV1’s potential to deliver long-term clinical impact for the patients. The observed late peaks in the IR are remarkable and often surpass the SIs detected during the treatment period. Such late peaks reflect complex dynamics of the anti-hTERT peptide response, elicited by tumor antigen release or subsequent therapy rather than the vaccine itself. The broadening of the IR occurring during these peaks may result from intramolecular epitope spreading, as has been previously observed with hTERT peptide vaccination.”
…og er også derfor det er spennede å få oppdaterte data fra nettopp denne studien senere i år.
20 Likes
Tror ikke det var tilfeldig at denne meldingen kom nå sent i dag. Abstraktene til ASCO konferansen blir i disse dager offentliggjort og de kan ikke endres før konferansen 2 -3 juni. Siden U ikke deltar selv på denne kan de ved denne meldingen og artikkelen likevel kuppe oppmerksomheten i bransjen. Riktig Timing er alt. U kan dette også ser det ut til.
6 Likes
Sikker på at du ikke mangler en 0 der mister?
8 Likes
Stille det var her.
Må si jeg reagerte litt på emisjonen U kjørte sist.
Men takk & lov at de hentet tilstrekkelig til å ikke måtte ut
med lua i hånda i dagens marked 
Her er nok en gluping som er ute med dype tanker på fredags kvelden.
Tonen Birgitte - tonen….
2 Likes
Ulti er kjedelig; alt dreier seg om spennende Nanaov!